Cargando…

Applying CiPA paradigm for assessing proarrhythmia risk of Covid-19 current off-label used therapies

Detalles Bibliográficos
Autores principales:	Delaunois, Annie, Hebeisen, Simon, Gryshkova, Vitalina, Lushbough, Isabel, Passini, Elisa, Trovato, Cristian, Rodriguez, Blanca, Valentin, Jean-Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483645/ http://dx.doi.org/10.1016/j.vascn.2021.107042

Ejemplares similares

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19
por: Delaunois, Annie, et al.
Publicado: (2021)

Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study
por: Delaunois, Annie, et al.
Publicado: (2023)

General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy
por: Li, Zhihua, et al.
Publicado: (2019)

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative
por: Li, Zhihua, et al.
Publicado: (2018)

Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive in vitro proarrhythmia assay (CiPA)
por: Yoon, Seung-Hyun, et al.
Publicado: (2023)

In silico assessment on TdP risks of drug combinations under CiPA paradigm
por: Qauli, Ali Ikhsanul, et al.
Publicado: (2023)

CiPA-compliant assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine
por: Amuzescu, Bogdan, et al.
Publicado: (2021)

Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept
por: Thomet, Urs, et al.
Publicado: (2021)

Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative
por: Park, Jin-Sol, et al.
Publicado: (2019)

Five years of the CiPA project (2013–2018): what did we learn?
por: Yim, Dong-Seok
Publicado: (2018)

Cross clinical-experimental-computational qualification of in silico drug trials on human cardiac purkinje cells for proarrhythmia risk prediction
por: Trovato, Cristian, et al.
Publicado: (2022)

Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs
por: Han, Sungpil, et al.
Publicado: (2019)

Mechanistic Model‐Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study
por: Vicente, Jose, et al.
Publicado: (2017)

Assessment of Multi‐Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study
por: Vicente, Jose, et al.
Publicado: (2019)

Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study
por: Millard, Daniel, et al.
Publicado: (2018)

Proarrhythmia Induced by Propafenone: What is the Mechanism?
por: Femenia, Francisco, et al.
Publicado: (2010)

Transgenic Rabbit Models in Proarrhythmia Research
por: Baczkó, István, et al.
Publicado: (2020)

Proarrhythmia and Oncotherapy: So Much To Be Done!
por: Kovacs, Richard J.
Publicado: (2021)

Cost-effectiveness of the hospital nutrition screening tool CIPA
por: Suárez-Llanos, José Pablo, et al.
Publicado: (2019)

HoPaCI-DB: host-Pseudomonas and Coxiella interaction database
por: Bleves, Sophie, et al.
Publicado: (2014)

Congenital Insensitivity to Pain with Anhidrosis (CIPA): A Case Report
por: Safari, A, et al.
Publicado: (2011)

A Case Report of Congenital Insensitivity to Pain and Anhidrosis (CIPA)
por: KARIMI, Mehran, et al.
Publicado: (2012)

Proarrhythmia in a Patient With Heart Failure on Therapy With Amiodarone
por: Semerdzhieva, Niya E, et al.
Publicado: (2021)

MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia
por: Uddin, Muhammad Erfan, et al.
Publicado: (2022)

Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
por: Polak, Sebastian, et al.
Publicado: (2015)

Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
por: Dutta, Sara, et al.
Publicado: (2017)

Congenital Insensitivity to Pain and Anhydrosis (CIPA) Syndrome; A Report of 4 Cases
por: Daneshjou, Khadije, et al.
Publicado: (2012)

Assessment of drug-induced proarrhythmias due to pilsicainide in patients with atrial tachyarrhythmias
por: Koike, Hideki, et al.
Publicado: (2016)

Necessity to evaluate PI3K/Akt signalling pathway in proarrhythmia
por: Ezeani, Martin, et al.
Publicado: (2017)

Corrigendum: Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
por: Dutta, Sara, et al.
Publicado: (2017)

The Role of the Food and Drug Administration in Drug Development: On the Subject of Proarrhythmia Risk
por: Thind, Munveer, et al.
Publicado: (2020)

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
por: Gatti, Milo, et al.
Publicado: (2020)

Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling Approach
por: Li, Zhihua, et al.
Publicado: (2019)

Right ventricular lead proarrhythmia: A novel intervention for an under-recognized phenomenon
por: Hayase, Justin, et al.
Publicado: (2017)

Uncertainty assessment of proarrhythmia predictions derived from multi-level in silico models
por: Kopańska, Karolina, et al.
Publicado: (2023)

Automated Algorithm for J-T(peak) and T(peak)-T(end) Assessment of Drug-Induced Proarrhythmia Risk
por: Johannesen, Lars, et al.
Publicado: (2016)

Effect of hydroxychloroquine on proarrhythmia risk assessment using human iPSC-derived cardiomyocytes
por: Yanagida, Shota, et al.
Publicado: (2021)

CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia
por: Hegyi, Bence, et al.
Publicado: (2021)

Phosphoprotein expression profiles in rat kidney injury: Source for potential mechanistic biomarkers
por: Gryshkova, Vitalina, et al.
Publicado: (2019)

Ci siamo!
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_4l2tfiem4c40o568c4tjn0ra0m